Urinary Incontinence and Overactive Bladder ClinicalTrial

This study is a double-blind, randomized, placebo controlledtrial of VESIcare for the treatment of overactive bladder in ParkinsonsDisease. The study also has anopen-label extension phase. This meansthat in the first part of the study, some people will get the placebo (sugarpill) and others will get the real drug.In the second half of the study, everyone will be on the real drug. There are a total of 7 clinic visits,approximately a month apart.

We are looking for PD patients aged 50-80 who have beenexperiencing symptoms of overactive bladder syndrome (OAB). Patients must be optimized on a treatmentregimen with anti-parkinsonian medication and at a stable dose during 4 weeksprior to the screening visit. Other inclusion and exclusion criteria can bedetermined by the study coordinator.

This study is taking place the University of South Florida in Tampa. Please contact: Kelly Sullivan at (813) 974-5909 for moreinformation.

Randomized, Double-Blind, Placebo-Controlled Trial ofLubiprostone (Amitiza) in the Treatment of Constipation Associated withParkinsons Disease

This is a double-blind,placebo-controlled study of Amitiza for the treatment of constipation inParkinsons Disease. This means thatsome people will be on the placebo and others will be on the real drug for theduration of the study.We are looking for PDpatients experience problems with constipation.

This study is taking place at the University of South Florida in Tampa. Please contact Israt Jahan at 813-974-5909 for moreinformation.